

STN SEARCH OF 02/18/2004

=> e collagenase

E1 2336 COLLAGEN/BI
E2 1 COLLAGENAN/BI
E3 293 --> COLLAGENASE/BI
E4 1 COLLAGENCONTIG/BI
E5 6 COLLAGENE/BI
E6 5 COLLAGENIC/BI
E7 2 COLLAGENOL/BI
E8 2 COLLAGENOLYTIC/BI
E9 1 COLLAGENON/BI
E10 14 COLLAGENOUS/BI
E11 90 COLLAGENS/BI
E12 2 COLLAGENVI/BI

=> s e3

L2 ANSWER 1 OF 293 REGISTRY COPYRIGHT 2004 ACS on STN
RN 604952-46-7 REGISTRY
CN Collagenase (Mycoplasma gallisepticum strain Rlow gene MGA_0839)
(9CI) (CA INDEX NAME)

OTHER NAMES:

CN GenBank AAP56476
CN GenBank AAP56476 (Translated from: GenBank AE016967)
FS PROTEIN SEQUENCE
MF Unspecified
CI MAN
SR GenBank
LC STN Files: CA, CAPLUS

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***

1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> sel L2 name

SELECT IS APPROXIMATELY 63% COMPLETE
E13 THROUGH E796 ASSIGNED

=> e elastase

E797 1 ELASTAN/BI
E798 1 ELASTANE/BI
E799 552 --> ELASTASE/BI
E800 2 ELASTASIN/BI
E801 5 ELASTAT/BI
E802 4 ELASTATIN/BI
E803 3 ELASTATINAL/BI
E804 1 ELASTATINIC/BI
E805 1 ELASTATINOL/BI
E806 1 ELASTCHEM/BI
E807 1 ELASTENE/BI
E808 1 ELASTEP/BI

=> s e799

L3 552 ELASTASE/BI
L3 ANSWER 1 OF 552 REGISTRY COPYRIGHT 2004 ACS on STN
RN 620690-36-0 REGISTRY
CN Secretory leukocyte elastase inhibitor (human) (9CI) (CA INDEX
NAME)

OTHER NAMES:

CN 21: PN: WO03090682 SEQID: 23 claimed protein
FS PROTEIN SEQUENCE
MF Unspecified

CI MAN
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

RELATED SEQUENCES AVAILABLE WITH SEQLINK

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***

1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> sel L3 name

E# OR SYSTEM LIMIT REACHED WHILE PROCESSING ANSWER 83

E809 THROUGH E999 ASSIGNED

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, AQUASCI, BIOBUSINESS,
BIOCOMMERCE, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CANCERLIT,
CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB, CROPU, DISSABS, DDFB, DDFU,
DGENE, DRUGB, DRUGMONOG2, ...' ENTERED AT 13:35:41 ON 18 FEB 2004

=> L2

227 FILE ADISCTI
61 FILE ADISINSIGHT
20 FILE ADISNEWS
271 FILE AGRICOLA
90 FILE ANABSTR
196 FILE AQUASCI
216 FILE BIOBUSINESS
97 FILE BIOCOMMERCE
16999 FILE BIOSIS
571 FILE BIOTECHABS
571 FILE BIOTECHDS
5452 FILE BIOTECHNO
1051 FILE CABA
4718 FILE CANCERLIT
14959 FILE CAPLUS
75 FILE CEABA-VTB
5 FILE CEN
63 FILE CIN
367 FILE CONFSCI
1 FILE CROPB
15 FILE CROPU
576 FILE DISSABS
286 FILE DDFB
4240 FILE DDFU
5657 FILE DGENE
286 FILE DRUGB
90 FILE DRUGMONOG2
50 FILE IMSDRUGNEWS
5635 FILE DRUGU
29 FILES SEARCHED...
35 FILE IMSRESEARCH
62 FILE EMBAL
15313 FILE EMBASE
3371 FILE ESBIODBASE
281 FILE FEDRIP
85 FILE FROSTI
115 FILE FSTA
9809 FILE GENBANK
12 FILE HEALSAFE

STN SEARCH OF 02/18/2004

806 FILE IFIPAT
 19 FILE IMSPRODUCT
 1634 FILE JICST-EPLUS
 124 FILE KOSMET
 2738 FILE LIFESCI
 1 FILE MEDICONF
 17615 FILE MEDLINE
 146 FILE NIOSHTIC
 100 FILE NTIS
 43 FILE OCEAN
 5496 FILE PASCAL
 107 FILE PHAR
 24 FILE PHARMAML
 110 FILE PHIN
 401 FILE PROMT
 4 FILE RDISCLOSURE
 14319 FILE SCISEARCH
 4 FILE SYNTHLINE
 6633 FILE TOXCENTER
 10854 FILE USPATFULL
 451 FILE USPAT2
 5 FILE VETB
 276 FILE VETU
 66 FILES SEARCHED...
 1378 FILE WPIDS
 1378 FILE WPINDEX
 L4 QUE L2 63 FILES HAVE ONE OR MORE ANSWERS
 L5 QUE "EC 3.4.24.3" OR(MICROBIAL COLLAGENASE) OR (CLOSTRIDIUM HISTOLYTICUM C
 OLLAGENASE) OR (CLOSTRIDIOPEPTIDASE A) OR (COLLAGENASE A) OR (COLLAGEN
 ASE I), 47 FILES HAVE ONE OR MORE ANSWERS
 L6 QUE (ACHROMOBACTER IOPHAGUS COLLAGENASE) OR (COLLAGENASE) OR(ASPERGILLOPEP
 TIDASE C) OR (NUCLEOLYSIN) OR (AZOCOLLAZE) OR (METALLOCOLLAGENASE) OR
 (SOYCOLLAGESTIN), 63 FILES HAVE ONE OR MORE ANSWERS
 L7 QUE (MATRIX METALLOPROTEINASE-8) OR (MATIRX METALLOPROTEINASE-18) OR (INTE
 RSTITIAL COLLAGENASE) , 43 FILES HAVE ONE OR MORE ANSWERS
 L8 QUE (L4 AND L5) AND (L6 AND L7) 21 FILES HAVE ONE OR MORE ANSWERS
 L9 QUE "EC3.4.21.37" OR (LEUKOCYTE ELASTASE) OR (LYSOSOMAL ELASTASE) OR (NEUT
 ROPHIL ELASTASE) OR (POLYMORPHONUCLEAR LEUKOCYTE ELASTASE) OR ELASTASE
 OR ELASZYM OR (SERINE ELASTASE) 63 FILES HAVE ONE OR MORE ANSWERS
 L10 QUE L3 AND L9 63 FILES HAVE ONE OR MORE ANSWERS
 L11 QUE (COMPOSITION OR FORMULATION OR FORMULA#####) 68 FILES HAVE ONE OR MORE
 ANSWERS
 L12 QUE (TREAT OR TREAT? OR THERAPY OR THERAPEU#####) 68 FILES HAVE ONE OR MORE
 ANSWERS
 L13 QUE (OBSTRUCTED OR BLOCKED OR CONSTRICTED) AND (?ARTERY OR VEIN OR AORTA O
 R VESSEL OR BLOOD VESSEL) 58 FILES HAVE ONE OR MORE ANSWERS
 L14 QUE ATHEROSCLEROSIS OR STENOSIS OR ARTERIOSCLEROSIS OR ((OBSTRUCTED OR BLO
 CKED OR CONSTRICTED) AND (?ARTERY OR ?VEIN)) 64 FILES HAVE ONE OR MORE ANSWERS
 L15 QUE L13 AND L14 56 FILES HAVE ONE OR MORE ANSWERS L16 QUE (HUMAN OR MAN OR
 HUMAN BEING OR HOMO SAPIENS) (5N) (PATIENT OR SUBJECT) 62 FILES HAVE ONE OR MORE
 ANSWERS
 L17 QUE L8 AND L10 7 FILES HAVE ONE OR MORE ANSWERS, 68 FILES SEARCHED IN STNINDEX
 L18 QUE L15 AND L16 30 FILES HAVE ONE OR MORE ANSWERS
 L19 QUE L12 AND L18 26 FILES HAVE ONE OR MORE ANSWERS
 L20 QUE L11 AND L8 8 FILES HAVE ONE OR MORE ANSWERS
 L21 QUE L11 AND L10 54 FILES HAVE ONE OR MORE ANSWERS
 L22 QUE L11 AND L17 5 FILES HAVE ONE OR MORE ANSWERS
 L23 QUE L19 AND L20 2 FILES HAVE ONE OR MORE ANSWERS

STN SEARCH OF 02/18/2004

=> d rank

F1 19 USPATFULL

F2 1 USPAT2

L24 QUE L19 AND L21 2 FILES HAVE ONE OR MORE ANSWERS

L25 QUE L19 AND L22 2 FILES HAVE ONE OR MORE ANSWERS

=> d rank

F1 18 USPATFULL

F2 1 USPAT2

L26 3 L23 AND L24 AND L25

L27 3 DUP REM L26 (0 DUPLICATES REMOVED)

L27 ANSWER 1 OF 3 USPATFULL on STN

AB The present invention relates to the compositions, methods, and applications of a novel approach to selective cellular targeting. The purpose of this invention is to enable the selective delivery and/or selective activation of effector molecules to target cells for diagnostic or therapeutic purposes. The present invention relates to multi-functional prodrugs or targeting vehicles wherein each functionality is capable of enhancing targeting selectivity, affinity, intracellular transport, activation or detoxification. The present invention also relates to ultra-low dose, multiple target, multiple drug chemotherapy and targeted immunotherapy for cancer treatment.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2003:200449 USPATFULL

TI Selective cellular targeting: multifunctional delivery vehicles, multifunctional prodrugs, use as antineoplastic drugs

IN Glazier, Arnold, Newton, MA, UNITED STATES

PA Drug Innovation & Design, Inc. (U.S. corporation)

PI US 2003138432 A1 20030724

AI US 2000-738625 A1 20001215 (9)

RLI Continuation of Ser. No. US 2000-712465, filed on 15 Nov 2000, ABANDONED

PRAI US 1999-165485P 19991115 (60)

US 2000-239478P 20001011 (60)

US 2000-241939P 20001010 (60)

DT Utility

FS APPLICATION

LREP N. Scott Pierce, Esq., HAMILTON, BROOK, SMITH & REYNOLDS, P.C., Two Militia Drive, Lexington, MA, 02421-4799

CLMN Number of Claims: 29

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 18716

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L27 ANSWER 2 OF 3 USPATFULL on STN

AB Invasive remodelling in a mammal may be inhibited by (1) inhibiting or abolishing the protein cleaving action of plasmin and (2) inhibiting or abolishing the protein cleaving action of at least one additional proteolytic enzyme active in invasive remodelling, such as a metalloprotease.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2002:186083 USPATFULL

TI Inhibition of invasive remodelling

IN Lund, Leif Roge, Copenhagen, DENMARK

Dano, Keld, Charlottenlund, DENMARK

Stephens, Ross, Charlottenlund, DENMARK

Brunner, Nils, Hellerup, DENMARK

Solberg, Helene, Hillerod, DENMARK

Holst-Hansen, Claus, Frederiksberg C, DENMARK

STN SEARCH OF 02/18/2004

Nielsen, John Romer, Copenhagen O, DENMARK

PI US 2002099004 A1 20020725

AI US 2001-995636 A1 20011129 (9)

RLI Continuation of Ser. No. US 1999-319464, filed on 27 Aug 1999, ABANDONED
A 371 of International Ser. No. WO 1997-DK555, filed on 8 Dec 1997,
UNKNOWN

PRAI DK 1996-1402 19961206

DT Utility

FS APPLICATION

LREP BROWDY AND NEIMARK, P.L.L.C., 624 Ninth Street, N.W., Washington, DC,
20001

CLMN Number of Claims: 39

ECL Exemplary Claim: 1

DRWN 16 Drawing Page(s)

LN.CNT 2781

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L27 ANSWER 3 OF 3 USPATFULL on STN

AB Disclosed are various compositions and methods for use in
achieving specific blood coagulation. This is exemplified by the
specific in vivo coagulation of tumor vasculature, causing tumor
regression, through the site-specific delivery of a coagulant using a
bispecific antibody.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 1999:27746 USPATFULL

TI Tissue factor compositions and ligands for the specific
coagulation of vasculature

IN Thorpe, Philip E., Dallas, TX, United States

Edgington, Thomas S., La Jolla, CA, United States

PA The Scripps Research Institute, La Jolla, CA, United States (U.S.
corporation)Board of Regents, The University of Texas System, Austin, TX, United
States (U.S. corporation)

PI US 5877289 19990302

AI US 1995-479733 19950607 (8)

RLI Continuation-in-part of Ser. No. US 1994-273567, filed on 11 Jul 1994
which is a continuation-in-part of Ser. No. US 1994-205330, filed on 2
Mar 1994, now patented, Pat. No. US 5855866 which is a
continuation-in-part of Ser. No. US 1992-846349, filed on 5 Mar 1992

DT Utility

FS Granted

EXNAM Primary Examiner: Feisee, Lila; Assistant Examiner: Bansal, Geetha P.

LREP Arnold White & Durkee L.L.P.

CLMN Number of Claims: 100

ECL Exemplary Claim: 1

DRWN 11 Drawing Figure(s); 8 Drawing Page(s)

LN.CNT 7148

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L28 1 L27 NOT PY> 1999

L28 ANSWER 1 OF 1 USPATFULL on STN

AB Disclosed are various compositions and methods for use in
achieving specific blood coagulation. This is exemplified by the
specific in vivo coagulation of tumor vasculature, causing tumor
regression, through the site-specific delivery of a coagulant using a
bispecific antibody.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

STN SEARCH OF 02/18/2004

AN 1999:27746 USPATFULL

TI Tissue factor compositions and ligands for the specific
coagulation of vasculature

IN Thorpe, Philip E., Dallas, TX, United States

Edgington, Thomas S., La Jolla, CA, United States

PA The Scripps Research Institute, La Jolla, CA, United States (U.S.
corporation)Board of Regents, The University of Texas System, Austin, TX, United
States (U.S. corporation)

PI US 5877289 19990302

AI US 1995-479733 19950607 (8)

RLI Continuation-in-part of Ser. No. US 1994-273567, filed on 11 Jul 1994
which is a continuation-in-part of Ser. No. US 1994-205330, filed on 2
Mar 1994, now patented, Pat. No. US 5855866 which is a
continuation-in-part of Ser. No. US 1992-846349, filed on 5 Mar 1992

DT Utility

FS Granted

EXNAM Primary Examiner: Feisee, Lila; Assistant Examiner: Bansal, Geetha P.

LREP Arnold White & Durkee L.L.P.

CLMN Number of Claims: 100

ECL Exemplary Claim: 1

DRWN 11 Drawing Figure(s); 8 Drawing Page(s)

LN.CNT 7148

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

The Contents of Case 09669051US_02182004

Qnum	Query	DB Name	Thesaurus	Operator	Plural
Q1	(((424/94.64)!.CCLS.)) and @pd > 20030401	USPT	None	ADJ	YES
Q2	(((424/423)!.CCLS.))) and @pd > 20030401	USPT	None	ADJ	YES
Q3	(((424/424)!.CCLS.))) and @pd > 20030401	USPT	None	ADJ	YES
Q4	(((424/425)!.CCLS.))) and @pd > 20030401	USPT	None	ADJ	YES
Q5	(Q1 and Q4) and @pd > 20030401	USPT	None	ADJ	YES
Q6	(Q2 and Q4) and @pd > 20030401	USPT	None	ADJ	YES
Q7	(Q3 and Q6) and @pd > 20030401	USPT	None	ADJ	YES
Q8	(Q1 and Q7) and @pd > 20030401	USPT	None	ADJ	YES
Q9	(Q1 and Q2) and @pd > 20030401	USPT	None	ADJ	YES
Q10	(Q3 and Q9) and @pd > 20030401	USPT	None	ADJ	YES
Q11	(Q6 and Q9) and @pd > 20030401	USPT	None	ADJ	YES
Q12	(Q4 and Q9) and @pd > 20030401	USPT	None	ADJ	YES
Q13	(Q7 and Q9) and @pd > 20030401	USPT	None	ADJ	YES
Q14	(514/1) and @pd > 20030401	USPT	None	ADJ	YES
Q15	(514/12) and @pd > 20030401	USPT	None	ADJ	YES
Q16	(514/21) and @pd > 20030401	USPT	None	ADJ	YES
Q17	(514/232.5) and @pd > 20030401	USPT	None	ADJ	YES
Q18	(514/232.8) and @pd > 20030401	USPT	None	ADJ	YES
Q19	(514/234.8) and @pd > 20030401	USPT	None	ADJ	YES
Q20	(514/255) and @pd > 20030401	USPT	None	ADJ	YES
Q21	(514/259) and @pd > 20030401	USPT	None	ADJ	YES
Q22	(514/319) and @pd >	USPT	None	ADJ	YES

	20030401				
Q23	(514/324) and @pd > 20030401	USPT	None	ADJ	YES
Q24	(514/411) and @pd > 20030401	USPT	None	ADJ	YES
Q25	(514/422) and @pd > 20030401	USPT	None	ADJ	YES
Q26	(514/428) and @pd > 20030401	USPT	None	ADJ	YES
Q27	(514/429) and @pd > 20030401	USPT	None	ADJ	YES
Q28	(514/441) and @pd > 20030401	USPT	None	ADJ	YES
Q29	(514/449) and @pd > 20030401	USPT	None	ADJ	YES
Q30	(514/473) and @pd > 20030401	USPT	None	ADJ	YES
Q31	(Q29 and Q30) and @pd > 20030401	USPT	None	ADJ	YES
Q32	(Q28 and Q31) and @pd > 20030401	USPT	None	ADJ	YES
Q33	(Q27 and Q31) and @pd > 20030401	USPT	None	ADJ	YES
Q34	(Q26 and Q31) and @pd > 20030401	USPT	None	ADJ	YES
Q35	(Q25 and Q31) and @pd > 20030401	USPT	None	ADJ	YES
Q36	(Q14 and Q15) and @pd > 20030401	USPT	None	ADJ	YES
Q37	(Q16 and Q36) and @pd > 20030401	USPT	None	ADJ	YES
Q38	(Q9 and Q37) and @pd > 20030401	USPT	None	ADJ	YES
Q39	(Q17 and Q18) and @pd > 20030401	USPT	None	ADJ	YES
Q40	(Q19 and Q39) and @pd > 20030401	USPT	None	ADJ	YES
Q41	(Q20 and Q21) and @pd > 20030401	USPT	None	ADJ	YES
Q42	(Q41 and Q22) and @pd > 20030401	USPT	None	ADJ	YES
Q43	(Q23 and Q42) and @pd > 20030401	USPT	None	ADJ	YES
Q44	(Q24 and Q43) and @pd > 20030401	USPT	None	ADJ	YES
Q45	(Q24 and Q25) and @pd > 20030401	USPT	None	ADJ	YES
Q46	(Q26 and Q45) and @pd > 20030401	USPT	None	ADJ	YES
	(Q27 and Q46) and				

Q47	@pd > 20030401	USPT	None	ADJ	YES
Q48	(Q28 and Q47) and @pd > 20030401	USPT	None	ADJ	YES
Q49	(Q29 and Q47) and @pd > 20030401	USPT	None	ADJ	YES
Q50	(Q30 and Q47) and @pd > 20030401	USPT	None	ADJ	YES
Q51	(Q31 and Q47) and @pd > 20030401	USPT	None	ADJ	YES
Q52	(Q31 and Q7) and @pd > 20030401	USPT	None	ADJ	YES
Q53	(Q31 and 40) and @pd > 20030401	USPT	None	ADJ	YES
Q54	(Q7 and Q53) and @pd > 20030401	USPT	None	ADJ	YES
Q55	(((biological conduit or artery or vasculature) same (human or mammal or animal)) near5 ((dilat\$5 or open or de-obstruct)near5 (collagenase or protease or collagen degrading enzyme))) and @pd > 20030401	USPT,PGPB,JPAB,EPAB,DWPI	None	ADJ	YES
Q56	(((biological conduit or artery or vasculature) near5 (human or mammal or animal)) near5 ((dilat\$5 or open or de-obstruct)near5 (collagenase or protease or collagen degrading enzyme))) and @pd > 20030401	USPT,PGPB,JPAB,EPAB,DWPI	None	ADJ	YES
Q57	(((biological conduit or artery or vasculature) near5 (human or mammal or animal)) near5 (dilat\$5 or open or de-obstruct)) and @pd > 20030401	USPT,PGPB,JPAB,EPAB,DWPI	None	ADJ	YES
Q58	(((stenosis or biological conduit or artery or vasculature) near5 (human or mammal or animal)) near5 (dilat\$5 or open or de-obstruct)) and @pd > 20030401	USPT,PGPB,JPAB,EPAB,DWPI	None	ADJ	YES

Q59	((collagenase or protease or collagen degrading enzyme)) and @pd > 20030401	USPT,PGPB,JPAB,EPAB,DWPI	None	ADJ	YES
Q60	(Q58 and Q59) and @pd > 20030401	USPT,PGPB,JPAB,EPAB,DWPI	None	ADJ	YES
Q61	((collagenase or protease) near5 (((stenosis or biological conduit or artery or vasculature) near5 (human or mammal or animal)) near5 (dilat\$5 or open or de-obstruct))) and @pd > 20030401	USPT,PGPB,JPAB,EPAB,DWPI	None	ADJ	YES
Q62	(collagenase or collagen degrading enzyme or collagen hydrolyzing enzyme) and @pd > 20030401	USPT,PGPB,JPAB,EPAB,DWPI	None	ADJ	YES
Q63	(Q62 and Q59) and @pd > 20030401	USPT,PGPB,JPAB,EPAB,DWPI	None	ADJ	YES
Q64	(Q58 and Q63) and @pd > 20030401	USPT,PGPB,JPAB,EPAB,DWPI	None	ADJ	YES

Case Operation

Run Case

Submit

Cancel